Could a simple breakfast replace the glucose drink for diabetes testing?

NCT ID NCT05789251

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial explores whether a standardized breakfast and a continuous glucose monitor can replace the traditional glucose drink test for diagnosing diabetes and prediabetes in people with Dunnigan's lipodystrophy, a rare genetic condition that causes severe insulin resistance. The study will compare the breakfast test and sensor readings against the standard oral glucose tolerance test to see if they agree. If they do, it could offer a more comfortable and practical way to monitor these patients, potentially improving adherence to regular check-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Standardized breakfast and continuous interstitial glucose monitoring
What this could lead to
If successful, this could offer a more acceptable alternative to the standard glucose drink for diagnosing diabetes in people with Dunnigan's lipodystrophy, improving follow-up and early detection.
What could go wrong
This is a small, early-stage study. The breakfast may not match the glucose drink's accuracy, and continuous monitoring might not align perfectly with standard tests. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUNNIGAN'S PARTIAL FAMILIAL LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de La Réunion

    Saint-Denis, 97400, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.